[{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\u003Cdiv id=\u0022republish_modal_form\u0022\u003E\u003Cform class=\u0022modal-form-example-modal-form ecl-form\u0022 data-drupal-selector=\u0022modal-form-example-modal-form\u0022 action=\u0022\/en\/article\/modal\/6967\u0022 method=\u0022post\u0022 id=\u0022modal-form-example-modal-form\u0022 accept-charset=\u0022UTF-8\u0022\u003E\u003Cp\u003EHorizon articles can be republished for free under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.\u003C\/p\u003E\n \u003Cp\u003EYou must give appropriate credit. We ask you to do this by:\u003Cbr \/\u003E\n 1) Using the original journalist\u0027s byline\u003Cbr \/\u003E\n 2) Linking back to our original story\u003Cbr \/\u003E\n 3) Using the following text in the footer: This article was originally published in \u003Ca href=\u0027#\u0027\u003EHorizon, the EU Research and Innovation magazine\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003ESee our full republication guidelines \u003Ca href=\u0027\/horizon-magazine\/republish-our-stories\u0027\u003Ehere\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003EHTML for this article, including the attribution and page view counter, is below:\u003C\/p\u003E\u003Cdiv class=\u0022js-form-item form-item js-form-type-textarea form-item-body-content js-form-item-body-content ecl-form-group ecl-form-group--text-area form-no-label ecl-u-mv-m\u0022\u003E\n \n\u003Cdiv\u003E\n \u003Ctextarea data-drupal-selector=\u0022edit-body-content\u0022 aria-describedby=\u0022edit-body-content--description\u0022 id=\u0022edit-body-content\u0022 name=\u0022body_content\u0022 rows=\u00225\u0022 cols=\u002260\u0022 class=\u0022form-textarea ecl-text-area\u0022\u003E\u003Ch2\u003EScientists can predict rare leukaemia 8 years before symptoms begin\u003C\/h2\u003E\u003Cp\u003EAcute myeloid leukaemia (AML) is a rare cancer usually detected at an advanced stage. \u2018It usually comes out of the blue,\u2019 said Dr Liran Shlush of the Weizmann Institute of Science in Israel. \u2018Most patients survive just a few weeks or months after diagnosis.\u2019\u003C\/p\u003E\u003Cp\u003EDiagnosing the disease earlier so that patients do not become fatally ill has been the goal of leukaemia researchers for decades. However, studying AML is challenging: by the time patients are identified, they are too sick to participate in clinical trials.\u003C\/p\u003E\u003Cp\u003EIn 2014, Dr Shlush and other scientists made a breakthrough by identifying cells where the disease begins. This paved the way for research on mutations (genetic changes) that are associated with a risk of developing AML.\u003C\/p\u003E\u003Cp\u003EThis was a significant step forward but presented new challenges. \u2018It turned out that almost 30% of the general population carries these early leukaemia mutations,\u2019 Dr Shlush explained. \u2018But AML is rare \u2013 this means that only a fraction of those with the mutations actually develop the disease. We needed a more specific way to predict who is at risk of developing AML.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EBiobank\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EThe team turned to the \u003Ca href=\u0022http:\/\/epic.iarc.fr\/\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003EEPIC biobank\u003C\/a\u003E \u2013 a collection of samples from more than 500,000 people in 10 European countries which was launched in the early 1990s. In addition to samples of blood and other cells, EPIC collected information on diet, lifestyle and medical history. Where these individuals were later diagnosed with cancer, this was recorded in the database so that researchers could go back and look for common factors that contribute to disease development.\u003C\/p\u003E\u003Cp\u003E\u003Cblockquote class=\u0022tw-text-center tw-text-blue tw-font-bold tw-text-2xl lg:tw-w-1\/2 tw-border-2 tw-border-blue tw-p-12 tw-my-8 lg:tw-m-12 lg:tw--ml-16 tw-float-left\u0022\u003E\n \u003Cspan class=\u0022tw-text-5xl tw-rotate-180\u0022\u003E\u201c\u003C\/span\u003E\n \u003Cp class=\u0022tw-font-serif tw-italic\u0022\u003E\u2018Most patients survive just a few weeks or months after diagnosis.\u2019\u003C\/p\u003E\n \u003Cfooter\u003E\n \u003Ccite class=\u0022tw-not-italic tw-font-normal tw-text-sm tw-text-black\u0022\u003EDr Liran Shlush, Weizmann Institute of Science, Israel\u003C\/cite\u003E\n \u003C\/footer\u003E\n\u003C\/blockquote\u003E\n\u003C\/p\u003E\u003Cp\u003EAs part of the \u003Ca href=\u0022https:\/\/cordis.europa.eu\/project\/rcn\/208086_en.html\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003EMAMLE\u003C\/a\u003E project, Dr Shlush\u2019s team studied EPIC blood samples to look for genetic differences in people who had gone on to develop AML and compare them with those who did not. This revealed around 260 genes commonly found in those who would later have the disease. Of those, 30 were found to be particularly important.\u003C\/p\u003E\u003Cp\u003EHowever, the mere presence of these genetic changes did not always mean individuals would get AML later in life. The volume of cells with these mutations and the presence of specific mutations were what made the difference.\u003C\/p\u003E\u003Cp\u003E\u2018When we sequenced these genes for people who developed AML and compared to a group of people of the same age who didn\u2019t get the disease, we found that what mattered was how much of these mutated cells were present and which mutations a person had,\u2019 said Dr Shlush. \u2018It\u2019s like risk factors for heart disease: the more bad cholesterol you have, the higher your chance of developing the disease.\u2019\u003C\/p\u003E\u003Cp\u003EBy testing for these mutations, researchers can predict the development of AML eight years before the patient notices any clinical symptoms. This new finding could be translated into a diagnostic tool. However, even at 99% accuracy, there would still be a high number of \u2018false positives\u2019 \u2013 people who are incorrectly told they are going to develop a devastating form of cancer in the years ahead.\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003E100% certainty\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003ETo narrow down the pool of high-risk patients, the team is now using information from electronic health records to single out individuals who have a combination of risk factors. This has helped them to identify people with specific genetic and other characteristics who doctors can say with almost 100% certainty will develop AML.\u003C\/p\u003E\u003Cp\u003EThe Israel-based scientists are designing a clinical trial to test a drug that they hope will slow \u2013 or prevent \u2013 the disease from advancing. Several existing therapies could be trialled, beginning with an antibiotic that already has approval from drug regulators for treating other conditions. Because it has been tested previously for safety, scientists can skip straight to large human trials to examine the drug\u2019s effectiveness in patients at high risk of AML.\u003C\/p\u003E\u003Cp\u003E\u2018We know this drug is very safe, we know a lot about dosing, and that it can be taken orally,\u2019 Dr Shlush said. \u2018We think that it could shrink the precancer stages and make the development of the disease much slower.\u2019 As AML is typically diagnosed in older people, slowing disease progression could mean that it never actually occurs in the patients\u2019 lifetime.\u003C\/p\u003E\u003Cp\u003EThe academic researchers have secured the cooperation of the company that makes the drug and are working through logistical challenges of testing a medication in healthy people, many of whom have never heard of AML.\u003C\/p\u003E\u003Cp\u003E\u2018We will have to screen thousands of people to find eligible participants,\u2019 Dr Shlush explained. \u2018That\u2019s the main obstacle and it presents ethical issues. Clinical trials are normally conducted in people who are attending a hospital because they are sick. We will need to contact at-risk individuals who are currently healthy and unaware of their risk of leukaemia.\u2019\u003C\/p\u003E\u003Cp\u003EOnce this is overcome, recruitment for the trial will begin. Building the infrastructure for the first study will be labour-intensive but the same population could be used to try several existing and new drugs. \u2018By tracking the type and volume of mutations in these individuals during treatment, we can see whether their risk grows, stabilises or disappears,\u2019 he said. \u2018We hope that this will help us to find something that inhibits disease development for a cancer where there is a major need.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cdiv class=\u0022moreinfoblock\u0022\u003E\n \u003Ch3\u003EHow does AML begin?\u003C\/h3\u003E\n \u003Cp\u003EAcute myeloid leukaemia is a disease of immature blood cells. Instead of developing into mature blood cells with finite lifespans, cells with compromised DNA or compromised regulation of DNA continue to divide. Eventually, these diseased cells take over and cause devastating effects on the body.\u003C\/p\u003E\u003Cp\u003EUnderstanding how AML occurs is difficult because the disease develops silently for many years before patients suddenly have severe symptoms. Researchers at Lund University in Sweden are using an alternative to studying human patients: they have developed a mouse model in which they can induce the disease.\u003C\/p\u003E\u003Cp\u003EProfessor David Bryder, who coordinates a project called\u0026nbsp;\u003Ca href=\u0022https:\/\/cordis.europa.eu\/project\/rcn\/185573_en.html\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003ELEUKEMIABARRIER\u003C\/a\u003E, says AML develops over a long period due to the cumulative effect of several changes in DNA. \u2018It\u2019s not a case of someone suffering a genetic mutation and coming down with the disease overnight,\u2019 he explained. \u2018There may be a first event \u2013 such as DNA damage \u2013 and then, much later, a second event, followed later by a third, and so on. \u2018Eventually this combination of changes adds up to an acute illness.\u2019\u003C\/p\u003E\u003Cp\u003EThe mouse model used at Lund University offers insights into how the disease develops by inducing genetic changes in mice and studying the events. This allows scientists to study how ordinary blood cells turn into leukaemia cells, and why the body fails to keep them in check as they divide uncontrollably.\u003C\/p\u003E\u003Cp\u003E\u2018Using our AML model, we have found, quite surprisingly, that blood stem cells \u2013 the most immature cells in the blood system \u2013 are not where leukaemia begins,\u2019 he said. \u2018That was quite unexpected because those cells were seen as the most likely source of disease.\u2019\u003C\/p\u003E\u003Cp\u003EInstead, the Lund team identified a whole range of cells at different stages of normal development, that were capable of giving rise to leukaemia. Now they can use this knowledge to explore possible new ways to diagnose and treat AML. If it works in mice, it could eventually be tested in humans. \u2018There is a big difference between mice and men but many of the same principles apply,\u2019 says Prof. Bryder.\u003C\/p\u003E\n\u003C\/div\u003E\n\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EThe research in this article was funded by the EU. If you liked this article, please consider sharing it on social media.\u003C\/em\u003E\u003C\/p\u003E\u003C\/textarea\u003E\n\u003C\/div\u003E\n\n \u003Cdiv id=\u0022edit-body-content--description\u0022 class=\u0022ecl-help-block description\u0022\u003E\n Please copy the above code and embed it onto your website to republish.\n \u003C\/div\u003E\n \u003C\/div\u003E\n\u003Cinput autocomplete=\u0022off\u0022 data-drupal-selector=\u0022form-2cdkbnszrlcfioqejtz1j1vjqr72jjdw5hd1sakrzvc\u0022 type=\u0022hidden\u0022 name=\u0022form_build_id\u0022 value=\u0022form-2CDkbNsZRlcFIOqEjTZ1j1Vjqr72jJdW5hD1Sakrzvc\u0022 \/\u003E\n\u003Cinput data-drupal-selector=\u0022edit-modal-form-example-modal-form\u0022 type=\u0022hidden\u0022 name=\u0022form_id\u0022 value=\u0022modal_form_example_modal_form\u0022 \/\u003E\n\u003C\/form\u003E\n\u003C\/div\u003E","dialogOptions":{"width":"800","modal":true,"title":"Republish this content"}}]